Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06879067 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
A Phase 1 study, sponsored by Tiziana Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT06879067: Completed Phase 1 study, sponsored by Tiziana Life Sciences.
NCT06879067 is a Phase 1 study that has completed, run by Tiziana Life Sciences. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06879067, a Phase 1 study, has completed, sponsored by Tiziana Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.
Primary Outcome
Establish the safety of administration of nasal Foralumab to healthy volunteers in escalating doses for 5 consecutive days. Two or more serious adverse events occur that are possibly, probably or definitely related to nasal Foralumab.
Interventions
- DRUG Placebo
- DRUG Foralumab Nasal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2020-11-09 |
| Phase | Phase 1 |
What the finished NCT06879067 record still lists
NCT06879067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06879067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06879067 about?
NCT06879067 is a clinical study titled "Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers". The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.
What is the current status of trial NCT06879067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-11-12. Estimated completion is 2020-11-09.
What interventions are being tested in trial NCT06879067?
The interventions under investigation include: Placebo (DRUG), Foralumab Nasal (DRUG).
Who is sponsoring clinical trial NCT06879067?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06879067's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI